A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
A phase I inhalation study on ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Retrospective study on the use of LABA/LAMA therapy (long acting bronchodilator agent/long acting muscarinic agent) in patients with severe COPD at first diagnosis. Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 Source: Eur Respir J 2013; 42: 972-981 Year: 2013
Metabolism of ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a b2 adrenoreceptor agonist, PF-00610355 Source: Annual Congress 2009 - New bronchodilators Year: 2009